Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.55 |
| ▸ | CA2 | P00918 | 11/20 | 0.55 |
| ▸ | MMP1 | P03956 | 11/20 | 0.55 |
| ▸ | MMP2 | P08253 | 11/20 | 0.55 |
| ▸ | MMP9 | P14780 | 11/20 | 0.55 |
| ▸ | MMP8 | P22894 | 11/20 | 0.55 |
| ▸ | MMP13 | P45452 | 11/20 | 0.55 |
| ▸ | ITGAV | P06756 | 1/20 | 0.48 |
| ▸ | ACLY | P53396 | 1/20 | 0.46 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.44 |
| ▸ | LOX | P28300 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8106699 | 0.81 | LOX (0.47) | CA1CA2ACLYBCAT2LOX | |
| SCHEMBL10699531 | 0.80 | CA1 (0.57) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL10153791 | 0.80 | CYP1A2 (0.49) | CA1CA2ITGAVACLYBCAT2 | |
| SCHEMBL29707981 | 0.79 | CA1 (0.52) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL15882505 | 0.79 | CA1 (0.52) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL4636106 | 0.78 | CA1 (0.55) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL45019 | 0.78 | CA2 (0.55) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL17498168 | 0.78 | BCAT2 (0.49) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL29707956 | 0.78 | MMP2 (0.50) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL29707965 | 0.78 | CA1 (0.50) | CA1CA2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240131311-A1 | DRUG-LOADED MEDICAL INSTRUMENT AND PREPARATION METHOD THEREFOR | SHANGHAI MICROPORT MEDICAL GROUP CO LTD (CN) | 2024-04-25 | — | — | US | claimed |
| EP-4295891-A1 | DRUG-LOADED MEDICAL INSTRUMENT AND PREPARATION METHOD THEREFOR | Shanghai MicroPort Medical (Group) Co., Ltd. (CN) | 2023-12-27 | — | — | EP | claimed |
| WO-2022174720-A1 | DRUG-LOADED MEDICAL INSTRUMENT AND PREPARATION METHOD THEREFOR | 上海微创医疗器械（集团）有限公司 | 2022-08-25 | — | — | WO | claimed |
| EP-2504003-B1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS INC (US) | 2016-11-09 | — | — | EP | claimed |
| US-20160081951-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. | 2016-03-24 | — | — | US | claimed |
| US-RE45314-E1 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-12-30 | — | — | US | claimed |
| EP-2504003-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | Cardioxyl Pharmaceuticals Inc. (US) | 2012-10-03 | — | — | EP | claimed |
| US-8030356-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | claimed |
| US-20110160200-A1 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | claimed |
| WO-2011063339-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | claimed |
| WO-2011063400-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | claimed |
| US-20250255862-A1 | METHODS OF TREATING HEART FAILURE WITH CARDIAC SARCOMERE ACTIVATORS | AMGEN INC. | 2025-08-14 | — | — | US | disclosed |
| US-20250161298-A1 | METHODS OF TREATING, AMELIORATING, OR PREVENTING HEART FAILURE, AND METHODS OF PROMOTING HEART MUSCLE GROWTH | UNIV YALE (US) | 2025-05-22 | — | — | US | disclosed |
| US-12295952-B2 | Methods of treating heart failure with cardiac sarcomere activators | CYTOKINETICS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| EP-4512470-A2 | METHODS OF TREATING HEART FAILURE WITH CARDIAC SARCOMERE ACTIVATORS | Amgen Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2011063339-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011063400-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| CN-101472576-A | N-hydroxysulfonamide derivatives as novel physiologically valuable nitroxyl donors | UNIV JOHNS HOPKINS (US) | 2009-07-01 | — | — | CN | disclosed |
| US-20070299107-A1 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | NATIONAL SCIENCE FOUNDATION | 2007-12-27 | — | — | US | disclosed |
| US-20070299107-A1 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | NATIONAL SCIENCE FOUNDATION | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160081951-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | NOS2, NOS3, NOS1 | CA1 3786/4885CA2 459/4885MMP1 1456/4885 |
| US-20110160200-A1 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension | NOS2, NOS3, NOS1 | CA1 3870/4885CA2 747/4885MMP1 1165/4885 |
| US-20070299107-A1 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | TNNI3, TNNC1, NME4 | CA1 2599/4885CA2 1456/4885MMP1 2327/4885 |
| US-20250255862-A1 | METHODS OF TREATING HEART FAILURE WITH CARDIAC SARCOMERE ACTIVATORS | TNNC1, TNNT2, TNNI3 | CA1 3658/4885CA2 1212/4885MMP1 1436/4885 |
| US-12295952-B2 | Methods of treating heart failure with cardiac sarcomere activators | TNNC1, TNNT2, TNNI3 | CA1 3658/4885CA2 1212/4885MMP1 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.